Monopar Therapeutics Inc.(MNPR)Earnings, Financials & Key RatiosMonopar Therapeutics Inc. (MNPR) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the $52.5 million cash position provides a substantial runway, the absence of revenue and the $93.4 million accumulated deficit suggest that the firm's valuation is entirely speculative and tied to binary clinical trial results.
Monopar Therapeutics Inc. (MNPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Monopar Therapeutics Inc. (MNPR) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.46vs $1.06+56.6% | — |
| Q2 2026 | Mar 27, 2026 | $0.61vs $0.51-19.1% | — |
| Q4 2025 | Nov 13, 2025 | $0.48vs $0.46-4.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.35vs $0.47+25.5% | — |
Recent stock market news and headlines for Monopar Therapeutics Inc. (MNPR)
Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer regulatory path, FDA designations, and even a possible Priority Review Voucher. MNPR's financing also seems safer this time around as they prepare ALXN1840's NDA and subsequent potential launch.
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company's late-stage candidate for the treatment of Wilson disease.
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.
Key metrics vs top competitors for Monopar Therapeutics Inc. (MNPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $95.22 | $637.88M | -51.47 | — | — | -14.22% | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $6.00 | $4.32M | -0.70 | -92.58% | -9388.51% | -131.3% | — |
Monopar Therapeutics Inc. (MNPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Monopar Therapeutics Inc. (MNPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 19, 2026·SEC
May 14, 2026·SEC
Apr 20, 2026·SEC
Get notified when MNPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Monopar Therapeutics Inc. (MNPR) stock FAQ — growth, dividends, profitability & financials explained
Monopar Therapeutics Inc. (MNPR) reported a net loss of $15.0M for fiscal year 2025.
Monopar Therapeutics Inc. (MNPR) has a return on equity (ROE) of -14.2%. Negative ROE indicates the company is unprofitable.
Monopar Therapeutics Inc. (MNPR) had negative free cash flow of $10.0M in fiscal year 2025, likely due to heavy capital investments.
